Tests give Fluad the all clear, says Italian agency
This article was originally published in Scrip
Results of initial tests carried out on the two batches of Novartis' flu vaccine Fluad that were suspended in Italy on 27 November as a result of reports of serious adverse events, including deaths, are "completely negative" and show there is nothing wrong with the quality of the products, says the regulatory agency AIFA.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.